" class="no-js "lang="en-US"> LifeArc - Medtech Alert
Thursday, August 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
LifeArc | Pharmtech Focus

LifeArc

About LifeArc

LifeArc

LifeArc® is a medical research charity advancing science and transforming medical research into treatments for patients.

We have a 25 year legacy of helping scientists and organisations advance their research into therapeutics and diagnostics for patients, including Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’s disease) and a test for antimicrobial resistance.

Find out more about how we fund, protect and develop much needed research at Lifearc.org or Twitter @lifearc1

Related Story

COVID-19

 RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies | Pharmtech Focus

RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies

May 17 2022

RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology […]

COVID-19

 LifeArc Co-founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth Up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2 | Pharmtech Focus

LifeArc Co-founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth Up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2

May 17 2022

LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed […]

COVID-19

 Genetic Study Gives Extensive Insights into Severe Covid-19 | Pharmtech Focus

Genetic Study Gives Extensive Insights into Severe Covid-19

March 8 2022

The world’s largest study of the genetics of critical Covid-19, involving more than 57,000 people, […]

Clinical Trials

 Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund | Pharmtech Focus

Cumulus Neuroscience Announces £6 million Funding Round

May 5 2021

Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led […]